Results 91 to 100 of about 145,320 (184)

The Role of Renal PLA2R Staining Combined with Serum PLA2R Antibody in Membranous Nephropathy Risk Stratification

, 2023
Background: This study aimed to examine the clinicopathological profiles and prognosis of membranous nephropathy in different subtypes classified by serum PLA2R antibody (SAb) and glomerular PLA2R antigen staining (GAg).
Xiaoxia Pan, Jing Xu, Hong Ren, Xiaofan Hu, Xinlu Wang, Chenni Gao, Jun Ma, Liyan Ni, Xialian Yu   +8 more
core   +1 more source

Complement activation products in the circulation and urine of primary membranous nephropathy

BMC Nephrology, 2019
Background Complement activation plays a substantial role in the pathogenesis of primary membranous nephropathy (pMN). C5b-9, C3c, MBL, and factor B have been documented in the subepithelial immune deposits. However, the changing of complement activation
Mu-fan Zhang, Jing Huang, Yi-miao Zhang, Zhen Qu, Xin Wang, Fang Wang, Li-qiang Meng, Xu-yang Cheng, Zhao Cui, Gang Liu, Ming-hui Zhao   +10 more
doaj   +1 more source

Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study

Renal Failure, 2020
Introduction Primary membranous nephropathy (PMN) is associated with the anti-phospholipase A2 receptor (anti-PLA2R) antibody in 70% of cases. Some anti-PLA2R-negative patients have the PLA2R antigen in renal tissue.
Peihong Yin, Junxian Wang, Wenyi Liang, Linda Zhan, Yuanhao Liu, Jian Lin, Xiaohong Chen, Yingqin He, Hongyun Jian, Zhibin Xie, Xiaofan Tan, Qing Ye, Fengxian Huang   +12 more
doaj   +1 more source

Secondary Renal Injury and Encephalopathy Syndrome Caused by Systemic Lupus Erythematosus With Overlapping Sjögren’s Syndrome in Children: A Case Report

Case Reports in Medicine, Volume 2025, Issue 1, 2025.
Systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) are chronic, multisystem disorders. When the two coexist, the manifestations become more complex and diverse, and early diagnosis and treatment are a key to improving the patient prognosis. However, to date, only scarce reports have been published, especially overlap syndrome. We review the
Xiao-Ling Li, Chun-Lei Liu, Yan Ma, Aneek Das Bhowmik   +3 more
wiley   +1 more source

Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy.

, 2014
Phospholipase A2 receptor 1 (PLA2R) is a target autoantigen in 70% of patients with idiopathic membranous nephropathy. We describe the location of a major epitope in the N-terminal cysteine-rich ricin domain of PLA2R that is recognized by 90% of human ...
Gummadova, Jennet, McKenzie, Edward A, Brenchley, Paul E; id_orcid, Jowitt, Thomas A; id_orcid, Fresquet, Maryline; id_orcid, Lennon, Rachel; id_orcid, O'Cualain, Ronan, Collins, Richard   +7 more
core   +1 more source

Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy – a retrospective cohort study

Romanian Journal of Internal Medicine, 2019
Introduction. Circulating autoantibodies against phospholipase A2 receptor (anti-PLA2R) are recognized as key elements in the pathogenesis of idiopathic membranous nephropathy.
Provatopoulou Simella, Kalavrizioti Dimitra, Stangou Maria, Kouri Maria-Nikoleta, Kalliakmani Pantellitsa, Papasotiriou Marios, Papachristou Evangelos, Goumenos Dimitrios S., Papagianni Aikaterini   +8 more
doaj   +1 more source

A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy

Practical Laboratory Medicine
Objective: The accurate detection of phospholipase A2 receptor (PLA2R) autoantibody is crucial in the diagnosis and monitoring of primary membranous nephropathy (pMN). While enzyme-linked immunosorbent assay (ELISA) is the commonly used detection method,
Xiaotao Ma, Ruiting Wang, Linting Wei, Pengfei Liu, Lanmei Jing, Jinghua Wang, Wei Dong, Xuefei Tian, Rongguo Fu   +8 more
doaj   +1 more source

The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery

Kidney International, 2019
The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary target in membranous nephropathy (MN) greatly advanced basic and clinical research. Primary MN is now considered a renal-limited autoimmune disease, with antibodies against PLA2R (aPLA2Rab) identified in 70-80 % of patients of various ethnic groups. Although the use of
van de Logt, A., van de Logt, A., Fresquet, M., Wetzels, J.F.M., Wetzels, J.F.M., Brenchley, P.   +5 more
openaire   +4 more sources

Supplementary Material for: Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy

, 2016
Background: M-type phospholipase A2 receptor (PLA2R) has been identified as the major target antigen in idiopathic membranous nephropathy (IMN). However, the role of glomerular PLA2R (gPLA2R) and the associations of serum anti-PLA2R antibody (sPLA2R-Ab ...
Wang Y. (2884271), Cao Y. (3217773), Wang C. (2954256), Wei Q. (3217770), Wang Y.-X. (3217785), Diao T.-T. (3217782), Li J.-S. (3217776), Zhao S.-L. (3217767), Wei S.-Y. (3217788), Li B. (3217779), Qin Y. (3217764)   +10 more
core   +1 more source

Clinical characteristics, anti-PLA2R antibody concentrations, and domain-specific antibody concentrations at initial diagnosis and 6 months follow-up (n = 25).

Clinical characteristics, anti-PLA2R antibody concentrations, and domain-specific antibody concentrations at initial diagnosis and 6 months follow-up (n = 25).
Yuan Qin (260617), Zhigang Hu (477325), Xiumei Zhou (126818), Qingqing Wu (1969732), Xue Yang (144876), Bo Lin (116835), Zijian Huang (10776416), Xiaobin Liu (344083), Liang Wang (23021), Ting Li (117885), Jing Xue (170229), Leting Zhou (12062753), Biao Huang (215504), Huiming Sheng (485213)   +13 more
core   +1 more source